Clinical Research in ALS & Related Disorders for Therapeutic Development (CReATe) - Career Enhancement Core

项目摘要/摘要 初级教师(医学博士和博士)的职业发展一直是Create Consortium的优先事项 通过其第一轮资助，我们的Create Scholars成功地获得了外部资金， 在影响较大的期刊上发表成果，确保初级教员职位，并在 财团和更广泛的领域内。创建职业提升核心计划的目标是 确定和选择希望从事罕见疾病研究的最有前途的候选人 专注于肌萎缩侧索硬化症和相关疾病；为这些创世学者提供支持、机会和 有利于他们成功成长的环境；并能协同促进他们的职业发展 CREATE联盟与罕见疾病临床研究网络(RDCRN)和 更广泛的神经学/神经科学界。为此，我们将为每个创客学者提供 通过一系列的培训、指导、资源和合作机会，并使每位学者能够 定制他们的职业提升计划，以满足他们自己的独特需求。可用的机会包括： (1)教学，通过国家CTSA计划NINDS卓越网络利用现有计划 在临床试验，NINDS临床试验方法课程，RDCRN R25罕见疾病认证计划， 和RDCRN罕见病临床研究会议；(2)本地和远程指导；(3) 建立网络，包括与其他机构的调查人员轮流访问；(4)旅行 津贴，以便能够参加国家和国际会议并介绍成果；(5)获得 创建资源(数据存储库、生物存储库、圣裘德云等)以及我们合作伙伴的 例如目标肌萎缩侧索硬化症(例如，人体组织核心)；以及(6)参与患者倡导团体和其他 战略合作伙伴计划，如ALS宣传日、科学审查委员会和患者支持 组。我们培训计划的意义和影响最终将由职业轨迹来判断 以及我们培训的内科研究人员和翻译科学家的成就。

Project Summary / Abstract Career enhancement of junior faculty (both MD and PhD) has been a priority for the CReATe Consortium through its first cycle of funding, with our CReATe Scholars being successful in securing extramural funding, publishing results in high impact journals, securing junior faculty positions, and emerging as leaders within the Consortium and more broadly within the field. The goals of the CReATe Career Enhancement Core are to identify and select the most promising candidates who wish to pursue a career in rare disease research focused on ALS and related disorders; provide these CReATe Scholars with support, opportunities and an environment that is conducive to their successful career growth; and synergize the career enhancement activities of the CReATe Consortium with those of the Rare Diseases Clinical Research Network (RDCRN) and the neurological/neuroscience community more broadly. To these ends, we will provide each CReATe Scholar with an array of training, mentorship, resource and partnership opportunities, and empower each Scholar to tailor their career enhancement program to match their own unique needs. Available opportunities will include: (1) didactics, leveraging existing programs through the National CTSA program, NINDS Network of Excellence in Clinical Trials, NINDS Clinical Trials Methods Course, the RDCRN R25 Rare Diseases Certificate Program, and RDCRN Clinical Conference on Research in Rare Diseases; (2) mentorship, both local and remote; (3) networking, including opportunities for visiting rotations with investigators at other institutions; (4) travel stipends, to enable participation and presentation of results at national and international meetings; (5) access to CReATe resources (data repository, biorepository, St. Jude Cloud, etc.) as well as those of our partners such as Target ALS (e.g. human tissue core); and (6) participation in patient advocacy group and other strategic partner initiatives such as ALS Advocacy Day, scientific review committees, and patient support groups. The significance and impact of our training program will ultimately be judged by the career trajectories and accomplishments of the physician investigators and translational scientists whom we train.